| Written | 2008-03 | Max Cayo, David Yu Greenblatt, Muthusamy Kunnimalaiyaan, Herbert Chen |
| Endocrine Surgery Research Laboratories, Department of Surgery, Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, Wisconsin, USA |
| Identity |
| ICD-Morpho | 8240/3 Carcinoid tumor |
| Atlas_Id | 5523 |
| Phylum | Neuro-Endocrine/Endocrine system::Carcinoid Tumor |
| Classification |
| Carcinoid tumors are the most common type of neuroendocrine (NE) tumor and comprise approximately half of all NE tumors of the gastrointestinal (GI) tract. They arise from enterochromaffin cells of the diffuse NE cells of the gut. Carcinoids are commonly classified according to their presumed derivation from the embryonic gut: Leotlela and colleagues suggested that only NE tumors which secrete serotonin, those of midgut embryologic origin, should be referred to as carcinoids. In 2000, the World Health Organization developed a classification system that dropped the term carcinoid entirely, recommending neuroendocrine tumor instead. This classification system uses three subsequent classifications based on malignant potential as assessed histologically: Despite these recommendations, the term carcinoid continues to be used by many clinicians and researchers. The incidence of carcinoid tumors is estimated at 1 to 2 cases per 100,000 people per annum. Because carcinoids often have an indolent clinical course, they are often misdiagnosed, and their true incidence is likely higher. A Swedish study, in which the incidence of carcinoid tumors was evaluated in surgical specimens and autopsies, estimated the true incidence of carcinoids to be 8.4 cases per 100,000. Sixty four percent of all carcinoids originate in the GI tract, and 28% originate in the lungs or bronchi. Within the GI tract, small intestinal carcinoids represent 29%, rectum 14%, stomach 5%, and appendix 5%. |
| Clinics and Pathology |
| Note | The diagnosis of a carcinoid tumor is based on histology and confirmed with immunohistochemical staining for neuroendocrine markers. Unfortunately, histological analysis alone cannot predict the aggressiveness or metastatic potential of carcinoids. Up to 75% of patients have metastases at the time of diagnosis. The following substances are secreted by carcinoid tumors: Carcinoid tumor production and release of these substances can lead to various symptoms in patients, including the carcinoid syndrome, which is characterized by skin flushing, wheezing and shortness of breath, diarrhea, and facial skin lesions. Another serious complication that can develop in patients with carcinoid tumors is valvular heart disease. These symptoms and complications related to carcinoid endocrinopathy can have a deleterious effect on patient quality of life. |
| Disease | Bronchial / Lung Carcinoid |
| Etiology | Lung and bronchial carcinoids are diagnosed most commonly in septuagenarians and are associated with smoking. |
| Epidemiology | Lung and bronchial carcinoids make up about 28% of carcinoids, and 2% of all primary lung tumors. |
| Clinics | The tumors are usually central in location and cause cough, hemoptysis, wheezing, and recurrent pneumonia. These tumors can be classified based on histological features as typical (two thirds) or atypical (one third). Atypical lung and bronchial carcinoids are generally larger at time of diagnosis than other carcinoids. These tumors are metastatic in up to 50% of cases and have a 5-year survival rate of only 40% to 75%. Typical lung and bronchial carcinoid tumors are found most often in a peripheral location, in the fifth decade of life, and rarely associated with the carcinoid syndrome. They are associated with ectopic adrenocorticotropic hormone (ACTH) secretion resulting in Cushings syndrome. These tumors are metastatic in 12% of cases and have a 5-year survival rate of 93%. |
| Pathology | One third of bronchial carcinoids demonstrate atypical histologic features and the more aggressive phenotype. |
| Treatment | For localized typical bronchial/lung carcinoids the preferred treatment is wedge or segmental lung resection. For histologically atypical carcinoids of the bronchi/lungs, more aggressive treatment is recommended such as lobectomy. As with all carcinoids, bronchopulmonary carcinoids usually do not respond to radiation therapy or chemotherapy, and use of these modalities should be considered experimental in this patient population. |
| Evolution | Typical carcinoid tumors are usually indolent, with metastases reported in less than 15% of cases. Atypical carcinoids pursue a more aggressive course, metastasizing to mediastinal lymph nodes in 30% to 50% of cases. |
| Prognosis | Long-term survival rates for patients with typical lung or bronchial carcinoid tumors following surgical resection exceed 85%. Long-term survival rates are significantly shorter for patients who undergo resection for atypical carcinoids - about 52% according to McCaughan et al. |
| Disease | Gastric Carcinoid |
| Etiology | Gastric carcinoid tumors are classified into 3 types: |
| Epidemiology | Gastric carcinoid tumors account for less than 1% of all gastric cancers. They comprise 5% of all GI carcinoids. Type 1 gastric carcinoids are the most common type, accounting for up to 75% of cases. Up to 10% of gastric carcinoids are Type 2, associated with Zollinger-Ellison syndrome. Between 15% and 25% of gastric carcinoids are sporadic, Type 3 gastric carcinoids. |
| Treatment | Most gastric carcinoids can be resected endoscopically. Cases involving larger, recurrent tumors require more extensive surgical resection. Antrectomy has been used in patients with chronic atrophic gastritis to eliminate the gastric production, and may cause the carcinoids to regress. The use of somatostatin analogs has resulted in gastric carcinoid tumor regression in patients with Zollinger-Ellison syndrome. In patients with sporadic Type 3 gastric carcinoids, which have a more aggressive biology, radical gastrectomy is the recommended treatment. |
| Evolution | Type 1 and 2 gastric carcinoids pursue an indolent course and generally do not metastasize. Sporadic Type 3 gastric carcinoids have a more aggressive course than Type 1 or Type 2. Most Type 3 gastric carcinoids are metastatic at presentation, portending a poor prognosis. |
| Disease | Small Intestinal Carcinoid |
| Epidemiology | Small intestinal carcinoid tumors account for approximately one third of all small bowel tumors. They comprise 29% of GI carcinoids. Small intestinal carcinoids are most commonly diagnosed in the sixth and seventh decades of life. |
| Clinics | Patients with small intestinal carcinoids frequently present with abdominal pain or small bowel obstruction. Approximately 5% to 7% of patients manifest symptoms of the carcinoid syndrome, and in these cases hepatic metastases are usually present. In patients with endocrinopathies, standard imaging techniques such as computed tomography (CT) and small bowel barium contrast studies often fail to localize the primary tumor. Small intestinal carcinoids are most frequently located in the distal ileum. |
| Treatment | Small intestinal carcinoids are treated by resection of the small bowel primary tumor together with associated mesenteric metastases. Most patients who have small bowel carcinoids are ultimately treated with octreotide, which is associated a high incidence of cholelithiasis. Because of this, cholecystectomy should be considered when carcinoids are surgically resected. |
| Prognosis | Tumor size is a poor predictor of metastases, and metastases have been reported in association with tumors smaller than 5 mm. The 5-year survival rate is 60% for patients with localized disease. It is 73% for those with regional metastases, and 36% for patients with distant metastases. |
| Disease | Appendiceal Carcinoid |
| Etiology | Approximately two-thirds of appendiceal carcinoid tumors arise in the tip of the appendix, where they are unlikely to cause symptoms of obstruction. Ten percent of appendiceal carcinoids occur in the base where they are more prone to obstruct the appendix and cause acute appendicitis. It has been proposed that the incidence of appendiceal carcinoid tumors parallels the activity of subepithelial NE cells, the source of these tumors. The density of these NE cells peaks in the second decade of life and then decreases. |
| Epidemiology | Carcinoid tumors are the most common tumor of the appendix, accounting for more than half of all appendiceal malignancies and discovered in seven of every 1,000 appendectomy specimens. They account for 5% of GI carcinoids and are more common in women than men. The mean age at presentation is 49 years. This may reflect the common patient age at appendectomy, when the tumors are often incidentally discovered. |
| Treatment | Simple appendectomy is indicated in patients with tumors less than 2 cm in diameter, based on historical data suggesting a low probability of metastasis. For tumors larger than 2 cm in diameter, right hemicolectomy is recommended. |
| Prognosis | Ninety-five percent of appendiceal carcinoid tumors are less than 2 cm in diameter. The incidence of metastases in these cases is low. In contrast, about 33% of patients who have appendiceal carcinoid tumors measuring more than 2 cm in diameter have either nodal or distant metastases. When disease is localized, the prognosis of appendiceal carcinoids is good. The 5-year survival rate is 94% for local disease, 85% for regional disease, and 34% when distant metastases are present. |
| Disease | Rectal Carcinoid |
| Epidemiology | Rectal carcinoids comprise 1-2% of all rectal cancers, and 14% of all GI carcinoids. Tumors less than 1 cm in diameter make up about 33% of all rectal carcinoids. |
| Clinics | Half of all rectal carcinoids are asymptomatic and are incidentally found during endoscopy performed for other indications, such as screening for colorectal cancer. Patients who are symptomatic usually present with rectal bleeding, pain, or constipation. |
| Treatment | For tumors less than 1 cm in diameter, local excision is indicated. Tumors between 1 and 2 cm in diameter, especially in combination with other factors such as symptoms at diagnosis, probably warrant more aggressive surgical treatment. Tumors over 2 cm in diameter are generally treated with a low anterior resection or abdominoperineal resection. |
| Prognosis | The size of the primary lesion is predictive of metastatic disease. Metastases occur in less than 5% of tumors that are less 1 cm in diameter but at a much higher rate when the primary lesions is greater than 2 cm in diameter. The 5-year survival rate is 81% for local disease, 47% when regional metastases are present, and 18% with distant metastases. |
| Genes involved and Proteins |
| Gene Name | MAP2 |
| Location | 2q34 |
| Note | Microtubule-associated protein 2 (MAP2) has been shown to be expressed specifically in neuronally differentiated cells, and is a useful marker for distinguishing non-neuroendocrine carcinomas of the lung from neuroendocrine lung tumors such as carcinoids. |
| Protein | MAP2 is a microtubule-associated protein important for the assembly of cytoskeletal components. |
| Gene Name | RAF1 |
| Location | 3p25 |
| Note | Raf-1 activation using an estrogen-inducible Raf-1 construct in human GI (BON) carcinoid cell line led to a marked reduction in neuroendocrine phenotypic markers such as human achaete-scute complex like-1 (ASCL1) and bioactive hormones and tumor markers 5-HT, chromogranin A (CgA), and synaptophysin. Treatment of GI carcinoid cells with Raf-1 activator ZM336372 led to a decrease in bioactive hormone levels, suppression of cellular proliferation, and an increase in cell cycle inhibitors p21 and p18, as well as a decrease in the neuroendocrine phenotypic marker ASCL1. |
| Gene Name | CTNNB1 |
| Location | 3p21 |
| Note | Alias: β-catenin Cytoplasmic accumulation of the β-catenin protein is present in about 30% of GI carcinoids and is absent in non-GI carcinoids. However, in tumors with accumulation of the protein, mutation in the β-catenin gene was not present. |
| Protein | β-catenin is part of the Wnt/β-catenin/APC signaling pathway which is complex and affects numerous cellular processes. The role of the gene product is varied and poorly understood in both GI and non-GI carcinoids. |
| Gene Name | HES1 |
| Location | 3q29 |
| Note | An increase in HES-1 expression in vitro causes suppression of pulmonary carcinoid cell growth. |
| Gene Name | CDKN1A |
| Location | 6p21 |
| Note | Alias: p21 Protein p21 up-regulation has been reported in appendiceal carcinoids. Its down-regulation or absence has been reported in pancreatic GI carcinoids. |
| Protein | A tumor suppressor, p21 is a cyclin-dependent kinase inhibitor. |
| Gene Name | VEGFA |
| Location | 6p12 |
| Note | Alias: VEGF Vascular endothelial growth factor (VEGF) expression has been demonstrated in a variety of bronchopulmonary and GI carcinoids. Tumor VEGF expression level corresponds to presence and number of metastases. Multiple genes in the VEGF pathway reside in regions of frequent mutation in neuroendocrine and carcinoid tumors. The VEGF pathway is important in angiogenesis, and is implicated in a multitude of neoplasms. Reduction in VEGF expression causes reduction in tumor microvessel density and growth. |
| Gene Name | CDKN2A |
| Location | 9p21 |
| Note | Alias: p16. Loss of heterozygosity in the p16 gene is present in 23% of carcinoids. |
| Protein | The p16 gene is a tumor suppressor. The p16 protein is a cyclin-dependent kinase inhibitor whose loss can lead to cell cycle abnormalities. |
| Gene Name | NOTCH1 |
| Location | 9q34.3 |
| Note | Notch-1 signaling is minimal or absent in GI Carcinoids. |
| Protein | Notch-1 protein functions either as a tumor suppressor or oncogenic protein depending on cellular context. Expression of active Notch-1 via adenoviral vector or inducible retroviral vector in GI carcinoid cells resulted in growth suppression and significant reduction in NE tumor markers such as 5-HT, CgA, synaptophysin, neuron specific enolase (NSE), and ASCL1, confirming the tumor suppressor role of Notch-1 signaling in carcinoid tumors. Treatment of human carcinoid cancer cells with histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoyl bishydroxamic acid (SBHA) resulted in activation of Notch-1 signaling and inhibition of carcinoid cell growth in vitro and in vivo. These findings suggest that Notch-1 activation with HDAC inhibitors may be an attractive approach for the treatment of these tumors. |
| Gene Name | MEN1 |
| Location | 11q13 |
| Note | Spanning 9 Kb and containing 10 exons. Carcinoids have been reported in association with multiple endocrine neoplasia type 1 (MEN1) since 1953. The MEN1 gene was sequenced and cloned in 1997. Since this time, a plethora of mutations have been discovered in the MEN1 gene, many with phenotypic consequences. Carcinoids are found in about 16-20% of patients with MEN1. |
| Protein | The MEN1 gene codes for the 610-amino acid protein menin, whose function is unknown. |
| Gene Name | CCND1 |
| Location | 11q13 |
| Note | Cyclin D1 up-regulation has been reported in appendiceal carcinoids. |
| Protein | Cyclin D1 forms a complex with cyclin-dependent kinases and acts to promote the cell cycle. |
| Gene Name | SDHD |
| Location | 11q23 |
| Note | Alternatively called PGL and PGL1 Succinate dehydrogenase complex subunit D (SDHD) is a tumor suppressor gene. Mutations in this gene are reported in 22% of ileal and duodenal carcinoids, and are not typically present in non-midgut carcinoids. |
| Protein | SDHD is a subunit of the succinate dehydrogenase complex on the inner mitochondrial membrane which is involved in the citric acid cycle and electron transport chain of metabolism. It has been postulated though not confirmed that the loss of functionality of this subunit causes a hypoxic response in affected cells that contributes to the tumor phenotype. |
| Gene Name | CDKN1B |
| Location | 12p13 |
| Note | Alias: p27 Protein p27 down-regulation or absence has been reported in pancreatic GI carcinoids. |
| Protein | A tumor suppressor, p27 is a cyclin-dependent kinase inhibitor. |
| Gene Name | NF1 |
| Location | 17q11.2 |
| Note | Loss of heterozygosity mutations in the neurofibromin 1 (NF1) gene have been reported in association with gastric carcinoids. NF1 is most commonly associated with the disease neurofibromatosis type 1. |
| Protein | NF1 encodes the protein called neurofibromin, a negative regulator of the Ras oncogene. Loss of NF1 activity also leads to constitutively active mTOR and tumor formation. |
| Gene Name | BCL2 |
| Location | 18q21 |
| Note | The bcl-2 family of proteins affects the growth of pulmonary carcinoids. The protein bcl-2 is expressed at higher levels in atypical pulmonary carcinoids than in typical pulmonary carcinoids. The protein bcl-x is expressed at higher levels in typical pulmonary carcinoids. It is possible that this balance is responsible for the more aggressive clinical course of atypical pulmonary carcinoids. |
| Protein | The bcl-2 protein is thought to be anti-apoptotic whereas the bcl-x protein is thought to be pro-apoptotic. |
| To be noted |
| Tumor Markers: Elevated urine levels of the serotonin (5-HT) breakdown product 5-HIAA is a highly specific indicator of midgut (small bowel, gastric) carcinoids. It is not useful in monitoring foregut (bronchial, lung) or hindgut (rectal) carcinoids, as these do not typically secrete serotonin. Chromogranin A (CgA) is an acidic glycoprotein that is contained in the neurosecretory vesicles of NE cells. It is an elementary tumor marker in NE tumor diseases, including carcinoids. CgA is more sensitive than urinary 5-HIAA and is useful in carcinoids of the fore-, mid-, and hindgut. In the clinical setting, CgA has been used an indicator of response to treatment. |
| Bibliography |
| Malignant tumors of the small intestine. |
| Barclay TH, Schapira DV. |
| Cancer. 1983 Mar 1;51(5):878-81. |
| PMID 6821853 |
| Carcinoid tumours. Frequency in a defined population during a 12-year period. |
| Berge T, Linell F. |
| Acta Pathol Microbiol Scand [A]. 1976 Jul;84(4):322-30. |
| PMID 961424 |
| Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. |
| Burke AP, Thomas RM, Elsayed AM, Sobin LH. |
| Cancer. 1997 Mar 15;79(6):1086-93. |
| PMID 9070484 |
| Bronchial carcinoid--twenty years' experience defines a selective surgical approach. |
| Chughtai TS, Morin JE, Sheiner NM, Wilson JA, Mulder DS. |
| Surgery. 1997 Oct;122(4):801-8. |
| PMID 9347859 |
| 71,000 Human Appendix Specimens. a Final Report, Summarizing Forty Years' Study |
| Collins DC. |
| Am J Proctol. 1963 Dec;14:265-81. |
| PMID 14098730 |
| Tumor markers in neuroendocrine tumors. |
| Eriksson B, Oberg K, Stridsberg M. |
| Digestion. 2000;62 Suppl 1:33-8. |
| PMID 10940685 |
| Bronchial carcinoid tumors: long-term outcome after surgery. |
| Fiala P, Petraskova K, Cernohorsky S, Kinkor Z, Krepela E, Zatloukal P. |
| Neoplasma. 2003;50(1):60-5. |
| PMID 12687280 |
| Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. |
| Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, Kramer MR. |
| Chest. 2001 Jun;119(6):1647-51. |
| PMID 11399686 |
| Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. |
| Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M, Chen H. |
| Oncologist. 2007 Aug;12(8):942-51. |
| PMID 17766653 |
| Bronchial carcinoid tumors: a retrospective analysis of 126 patients. |
| Harpole DH Jr, Feldman JM, Buchanan S, Young WG, Wolfe WG. |
| Ann Thorac Surg. 1992 Jul;54(1):50-4; discussion 54-5. |
| PMID 1610254 |
| Rectal carcinoids: the most frequent carcinoid tumor. |
| Jetmore AB, Ray JE, Gathright JB Jr, McMullen KM, Hicks TC, Timmcke AE. |
| Dis Colon Rectum. 1992 Aug;35(8):717-25. |
| PMID 1643994 |
| The NF1 tumor suppressor critically regulates TSC2 and mTOR. |
| Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. |
| Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8. Epub 2005 Jun 3. |
| PMID 15937108 |
| Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. |
| Koura AN, Giacco GG, Curley SA, Skibber JM, Feig BW, Ellis LM. |
| Cancer. 1997 Apr 1;79(7):1294-8. |
| PMID 9083149 |
| Clinical presentation and management of carcinoid tumors. |
| Kulke MH. |
| Hematol Oncol Clin North Am. 2007 Jun;21(3):433-55; vii-viii. |
| PMID 17548033 |
| Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. |
| Kunnimalaiyaan M, Chen H. |
| Oncologist. 2007 May;12(5):535-42. |
| PMID 17522241 |
| Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. |
| Kytola S, Nord B, Elder EE, Carling T, Kjellman M, Cedermark B, Juhlin C, Hoog A, Isola J, Larsson C. |
| Genes Chromosomes Cancer. 2002 Jul;34(3):325-32. |
| PMID 12007193 |
| Treatment of advanced carcinoid tumors. |
| Lal A, Chen H. |
| Curr Opin Oncol. 2006 Jan;18(1):9-15. |
| PMID 16357558 |
| Genetics of neuroendocrine and carcinoid tumours. |
| Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV. |
| Endocr Relat Cancer. 2003 Dec;10(4):437-50. |
| PMID 14713256 |
| Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma. |
| Liu Y, Sturgis CD, Grzybicki DM, Jasnosz KM, Olson PR, Tong M, Dabbs DD, Raab SS, Silverman JF. |
| Mod Pathol. 2001 Sep;14(9):880-5. |
| PMID 11557784 |
| A study of the histopathogenesis of carcinoid tumors of the small intestine and appendix. |
| Lundqvist M, Wilander E. |
| Cancer. 1987 Jul 15;60(2):201-6. |
| PMID 3297280 |
| Surgical treatment of mid-gut carcinoid tumors. |
| Makridis C, Oberg K, Juhlin C, Rastad J, Johansson H, Lorelius LE, Akerstrom G. |
| World J Surg. 1990 May-Jun;14(3):377-83; discussion 384-5. |
| PMID 2368441 |
| Carcinoid tumors of the lung: do atypical features require aggressive management? |
| Marty-Ane CH, Costes V, Pujol JL, Alauzen M, Baldet P, Mary H. |
| Ann Thorac Surg. 1995 Jan;59(1):78-83. |
| PMID 7818364 |
| Multiple endocrine neoplasia type 1: clinical and genetic topics. |
| Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. |
| Ann Intern Med. 1998 Sep 15;129(6):484-94. |
| PMID 9735087 |
| Bronchial carcinoids. Review of 124 cases. |
| McCaughan BC, Martini N, Bains MS. |
| J Thorac Cardiovasc Surg. 1985 Jan;89(1):8-17. |
| PMID 2981373 |
| Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification. |
| Mezzetti M, Raveglia F, Panigalli T, Giuliani L, Lo Giudice F, Meda S, Conforti S. |
| Ann Thorac Surg. 2003 Dec;76(6):1838-42. |
| PMID 14667595 |
| Gastric carcinoids. The Yale Experience. |
| Modlin IM, Gilligan CJ, Lawton GP, Tang LH, West AB, Darr U. |
| Arch Surg. 1995 Mar;130(3):250-5; discussion 255-6. |
| PMID 7887791 |
| A 5-decade analysis of 13,715 carcinoid tumors. |
| Modlin IM, Lye KD, Kidd M. |
| Cancer. 2003 Feb 15;97(4):934-59. |
| PMID 12569593 |
| An analysis of 8305 cases of carcinoid tumors. |
| Modlin IM, Sandor A. |
| Cancer. 1997 Feb 15;79(4):813-29. |
| PMID 9024720 |
| Carcinoid tumors of the lung. |
| Okike N, Bernatz PE, Woolner LB. |
| Ann Thorac Surg. 1976 Sep;22(3):270-7. |
| PMID 962413 |
| Bronchial carcinoids: a review of 60 patients. |
| Rea F, Binda R, Spreafico G, Calabr F, Bonavina L, Cipriani A, Di Vittorio G, Fassina A, Sartori F. |
| Ann Thorac Surg. 1989 Mar;47(3):412-4. |
| PMID 2930304 |
| Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. |
| Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. |
| World J Surg. 1996 Feb;20(2):168-72. |
| PMID 8661813 |
| Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience. |
| Schrevens L, Vansteenkiste J, Deneffe G, De Leyn P, Verbeken E, Vandenberghe T, Demedts M. |
| Lung Cancer. 2004 Jan;43(1):39-45. |
| PMID 14698535 |
| The topographical and age distributions of neuroendocrine cells in the normal human appendix. |
| Shaw PA. |
| J Pathol. 1991 Jul;164(3):235-9. |
| PMID 1890548 |
| Carcinoid tumors. |
| Sippel RS, Chen H. |
| Surg Oncol Clin N Am. 2006 Jul;15(3):463-78. |
| PMID 16882492 |
| Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. |
| Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. |
| Lung Cancer. 2002 Aug;37(2):127-35. |
| PMID 12140134 |
| Clinical features and therapy of typical and atypical bronchial carcinoid tumors (grade 1 and grade 2 neuroendocrine carcinoma). |
| Smolle-Juttner FM, Popper H, Klemen H, Pinter H, Pongratz-Roeger M, Smolle J, Friehs G. |
| Eur J Cardiothorac Surg. 1993;7(3):121-4; discussion 125. |
| PMID 8384862 |
| Gastric carcinoid: germline and somatic mutation of the neurofibromatosis type 1 gene. |
| Stewart W, Traynor JP, Cooke A, Griffiths S, Onen NF, Balsitis M, Shah AA, Upadhyaya M, Tobias ES. |
| Fam Cancer. 2007;6(1):147-52. |
| PMID 16944271 |
| Nuclear translocation of beta-catenin protein but absence of beta-catenin and APC mutation in gastrointestinal carcinoid tumor. |
| Su MC, Wang CC, Chen CC, Hu RH, Wang TH, Kao HL, Jeng YM, Yuan RH. |
| Ann Surg Oncol. 2006 Dec;13(12):1604-9. Epub 2006 Sep 29. |
| PMID 17009161 |
| Carcinoid tumors of the appendix. Mesoappendiceal extension and nodal metastases. |
| Syracuse DC, Perzin KH, Price JB, Wiedel PD, Mesa-Tejada R. |
| Ann Surg. 1979 Jul;190(1):58-63. |
| PMID 464679 |
| Treatment of type II gastric carcinoid tumors with somatostatin analogues. |
| Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. |
| N Engl J Med. 2000 Aug 24;343(8):551-4. |
| PMID 10954763 |
| Typical and atypical bronchial carcinoids. |
| Torre M, Barberis M, Barbieri B, Bonacina E, Belloni P. |
| Respir Med. 1989 Jul;83(4):305-8. |
| PMID 2608951 |
| A novel missense mutation of the MEN1 gene in a multiple endocrine neoplasia type 1 patient associated with carcinoid syndrome. |
| Ukita C, Yamaguchi M, Tanaka T, Shigeta H, Nishikawa M. |
| Intern Med. 2003 Nov;42(11):1112-6. |
| PMID 14686752 |
| Molecular targeted therapy for neuroendocrine tumors. |
| Yao JC, Hoff PM. |
| Hematol Oncol Clin North Am. 2007 Jun;21(3):575-81; x. |
| PMID 17548041 |
| Apoptosis and expression of bcl-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung. |
| Zirbes TK, Lorenzen J, Baldus SE, Moenig SP, Wolters U, Ottlik A, Thiele J, Hölscher AH, Dienes HP. |
| Histopathology. 1998 Aug;33(2):123-8. |
| PMID 9762544 |
| Citation |
| This paper should be referenced as such : |
| Cayo, M ; Greenblatt, DY ; Kunnimalaiyaan, M ; Chen, H |
| Carcinoid Tumors |
| Atlas Genet Cytogenet Oncol Haematol. 2009;13(3):240-245. |
| Free journal version : [ pdf ] [ DOI ] |
| On line version : http://AtlasGeneticsOncology.org/Tumors/CarcinoidID5523.html |
| Other genes implicated (Data extracted from papers in the Atlas) [ 5 ] |
| Genes | AIP | ASCL1 | NOTCH1 | PDCD6 | RAF1 |
| External links |
| REVIEW articles | automatic search in PubMed |
| Last year articles | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Fri Jun 30 11:24:46 CEST 2017 |
For comments and suggestions or contributions, please contact us